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TRANSLATIONAL RELEVANCE
Although the majority of pediatric patients with acute lymphoblastic leukemia (ALL) have excellent outcomes, the prognosis remains poor in patients with high-risk disease and those who relapse, especially when allogeneic hematopoeietic stem cell transplantation is not feasible. Several new treatments are being investigated, including immune-based therapies.
Immunotherapy approaches have included vaccines, which generally target a single HLArestricted epitope. More recently, CD19-specific antibodies and CD19CAR gene-modified Tcells have shown remarkable successes for CD19 + malignancies, including pediatric ALL.
Targeting single antigens can eliminate cells expressing the targeted epitope, but can lead to outgrowth of antigen-negative populations. This paper validates a novel approach expanding Tcells from pediatric patients with ALL, targeting multiple tumor-associated antigens.
Simultaneous targeting of multiple antigens may decrease the risk of tumor immune escape when T cells are administered in vivo. Hence, this innovative immunotherapeutic strategy has the potential to increase the potency of vaccines and CD19-directed therapies to prevent relapse and improve the prognosis of patients with high-risk ALL.
Research.
on October 2, 2017. © 2013 American Association for Cancer clincancerres.aacrjournals.org Downloaded from Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on July 9, 2013; DOI: 10.1158/1078-0432.CCR-13-0955
INTRODUCTION
The outcome of patients with acute lymphoblastic leukemia (ALL), the most common childhood leukemia, has significantly improved with the advent of intensive chemotherapy regimens that can achieve cure rates of over 90%. However, for patients classified as high-risk, according to NIH criteria, or those who relapse, the best chance of cure is allogeneic hematopoietic stem cell transplantation (HSCT) (1). Not all patients are eligible for HSCT and over a third of transplanted patients still relapse after HSCT for ALL (1, 2). Therefore, strategies to prevent relapse in patients with ALL, classified as high risk, are needed. Immunotherapy is an effective tool for the treatment of leukemia. First demonstrated in patients with chronic myeloid leukemia (CML) the infusion of unselected donor lymphocytes (DLI) has been shown to stably eradicate minimal residual disease (3, 4) . In ALL, a high absolute lymphocyte count at the end of induction therapy is associated with improved survival, suggesting the importance of the host immune response in controlling disease (5). In addition, in the transplant setting there is strong evidence for a T-cell mediated graft-versus-leukemia effect (6). However, DLI rarely induces responses in patients relapsing after HSCT (7-9), suggesting that the anti-leukemic effects of T cells may require augmentation to prevent or treat relapsed ALL. Recently, T cells genetically modified with chimeric antigen receptors (CARs) targeting a CD19 epitope were shown to induce prolonged remissions in relapsed ALL patients (10, 11) . However, relapse can occur by selection of a CD19 negative leukemia cell population (12) . We have shown that T cells with native tumor-specificity can be activated and expanded using single epitopes of tumor antigens as stimulus in vitro for adoptive cell transfer or in vivo in response to vaccines (13, 14) .
Furthermore, we have demonstrated that, in healthy donors, it is possible to induce T cells specific for multiple tumor antigens which can target and kill acute myeloid leukemia cells (15).
Author Manuscript Published OnlineFirst on July 9, 2013; DOI: 10.1158 /1078 We therefore chose to evaluate the feasibility of generating and expanding tumor antigenspecific T-cell lines from patients with ALL as a potential adoptive immunotherapeutic strategy to prevent relapse in high risk patients or patients not eligible for allogeneic HSCT. Acute lymphoblastic leukemia cells express a number of tumor-associated antigens (TAA). We selected WT1 (16), Survivin (17, 18) , and PRAME (6, 20) as target antigens for the generation of tumor antigen-specific T cells with the aim of broadening the applicability of Tcell therapy to the majority of patients with ALL, and reducing immune escape by the leukemia through emergence of clones deficient in TAA.
In this study we have developed a novel strategy to activate autologous T cells targeting multiple tumor antigens. We demonstrated that by utilizing both autologous dendritic cells and PHA-blasts as antigen-presenting cells we can successfully expand TAA-specific T-cell lines from 50 patients with ALL during maintenance therapy, irrespective of NCI risk status or lymphocyte count.
MATERIALS AND METHODS

Patient samples
Peripheral blood was obtained from 50 pediatric patients with ALL, receiving maintenance chemotherapy at the Texas Children's Cancer Center. All families had provided written informed consent on treatment protocols approved by the Baylor College of Medicine Institutional Review 
Generation of antigen-presenting cells
Monocyte-derived dendritic cells (DC) were generated by plate adherence of PBMC. PBMC were incubated for 2 hours in DC media (Cellgro DC media, Cellgenix, Freiburg, Germany) supplemented with 2mM Glutamax. Non-adherent cells were collected and washed. Adherent cells were cultured in DC media in the presence of IL4 (1000U/ml) and GM-CSF (800U/ml) (both R&D, Minneapolis, MN). On day 5, immature DC were matured in DC media with a cytokine cocktail consisting of IL4 (1000U/ml), GM-CSF (800U/ml), IL6 (10ng/ml), TNFα (10ng/ml), IL1β (10ng/ml) (all R&D) and PGE2 (1µg/ml) (Sigma-Aldrich), and were harvested after 48 hours of maturation for use as antigen presenting cells (APC).
For phytohemagglutinin (PHA)-blast generation, PBMC were stimulated with the mitogen phytohemagglutinin-P (PHA-P, 5µg/ml; Sigma-Aldrich, St. Louis, MO) in presence of IL2 to promote blast formation (PHA-blasts). PHA-blasts were cultured in RPMI 1640 supplemented with 5% human serum (Gem Cell, Gemini Bio-Products, West Sacramento, CA) and 2mM
Glutamax (Invitrogen, Grand Island, NY) and Interleukin (IL) 2 (100U/ml) (Teceleukin, Chiron Therapeutics, Emeryville, CA).
Generation of TAA-specific T-cell lines
TAA-specific T-cell lines were generated from total PBMC. Matured DC were harvested and used as APC and peptide-pulsed with a mix of four peptide libraries (pepmixes, JPT Technologies, Berlin, Germany): WT1, Survivin, MAGE-A3 and PRAME. DC were used at a stimulator-to-effector ratio of 1:10. T cells were cultured in RPMI 1640 supplemented with 45% Clicks media (Irvine Scientific, Santa Ana, CA), 5% human AB serum and 2mM Glutamax. For initial stimulation, a cytokine mix containing IL7 (10ng/ml), IL12 (10ng/ml), IL15 (5ng/ml) and IL6 (100ng/ml) was added (15, 22) . T cells were re-stimulated with peptide-pulsed autologous Author Manuscript Published OnlineFirst on July 9, 2013; DOI: 10.1158 /1078 irradiated (30Gy) PHA-blasts at a ratio of 1:1 on day 10 to 12 and cultures were maintained in IL2 (50U/ml) supplemented media and re-stimulated every 7 days as described above for a minimum of 4 stimulation cycles, but could be kept in culture for up to 8 re-stimulations without loss of specificity. No further selection or enrichment of T cells was carried out at any point throughout the sensitization and expansion period.
IFNγ Enzyme-Linked Immunospot Assay (ELISpot)
Peptide recognition was tested in an Interferon-γ (IFNγ ) Enzyme-linked Immunospot (ELISpot) assay (23). Recognition of the pooled TAAs as well as single antigens was tested as compared to no-peptide (media) control (labeled as control in all graphs) and irrelevant peptide (NY-Eso-1), that was not used for T-cell generation.
Millipore Multi Screen HTS filter plates (Millipore, Billerica, MA) were coated with IFNγ capture antibody (Mabtech, Nacka Strand, Sweden) at a concentration of 10µg/ml over night at 4°C.
Plates were washed with PBS and blocked for 1 hour at 37°C to rule out non-specific protein binding. T cells were washed and re-suspended and stimulated with pepmix or single peptides at a concentration of 0.1mg/ml. The plates were incubated for 16-20 hours at 37°C. For development, plates were washed in PBS/0.05% Tween 20 and incubated with biotinylated IFNγ detection antibody (0.5µg/ml) (Mabtech) for 2 hours at 37°C, followed by incubation with streptavidin-coupled alkaline phosphatase complex (Vectastain, Vector Laboratories, Burlingame, CA) for 1 hour at room temperature and spots were developed by incubation with 3-Amino-9-ethylcarbazole substrate solution. Spot forming cells (SFC) were counted and evaluated by Zellnet Consulting (Fort Lee, NY) using an automated plate reader system (Karl Zeiss, Jena, Germany).
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HLA-blocking experiments
HLA-restriction of antigen recognition was tested in IFNγ−ELISpot using autologous PHA-blasts pulsed with the relevant peptide (positive control) or without peptide (negative control) and blocking antibodies against HLA class I and class II (both BD Biosciences, San Jose, CA, USA).
ELISpot plates were incubated and developed as described above. 
Co-culture with autologous blast samples
To test recognition of autologous blasts, TAA-specific T-cell lines were co-cultured with each patient's autologous leukemic bone marrow sample, which had been cryopreserved at diagnosis. Co-culture experiments were carried out at ratios of 10:1 or 5:1 (T cells : leukemic blasts) for 3 days in presence of IL2 (50U/ml). Nonspecific autologous T cells were used as negative controls. Leukemia cells were quantified by co-staining with anti-CD10 and CD19
antibodies and samples were acquired on a BD FACS Calibur Flow Cytometer using Count Bright absolute counting beads (Molecular Probes, Eugene, OR) for quantification of absolute cell counts.
Enzyme-linked immunosorbent assays
Detection of cytokine release in the supernatants of co-cultured CTL was analyzed by an Enzyme-linked immunosorbent assay (ELISA) specific for IFNγ and IL4 (both R&D). For detection of IFNγ a 96-well microplate was coated with anti IFNγ capture antibody and incubated overnight. Cell culture supernatants were incubated and specific binding of IFNγ was detected by incubation with a biotinylated detection antibody, streptavidin-coupled horseradishperoxidase and developed by incubation with substrate solution. Optical density of plates was read at 450nm with a wavelength correction at 570nm. For IL4, the same principle was applied and optical density determined at 490nm. Cytokine release was quantified in comparison to a specific standard; the assay was run in duplicates.
Colony forming unit assay
A colony forming unit (CFU) assay was carried out to show blast elimination in a long-term coculture. T cells were co-cultured with autologous leukemic blasts at a 10:1 ratio in IMDM medium (Invitrogen) substituted with 10% FBS and 2mM Glutamax for 6 hours. After this pre- 
Statistics
Data are summarized as mean ± standard deviation (SD) or mean ± standard error (SE), as noted in the text or figure legends. Student t-test was used to determine whether there was a statistically significant difference between samples, with two-tailed P values <0.05 indicating a significant difference.
RESULTS
TAA-specific T-cell lines can be reliably expanded from patients with ALL on maintenance therapy, irrespective of their NCI risk status or absolute lymphocyte count TAA-specific T-cell lines were generated from peripheral blood obtained from 50 patients with ALL, 26 designated as high risk and as 24 standard risk according to NCI-Rome criteria, during the maintenance phase of chemotherapy. Blood samples, collected at least 3 months after the start of maintenance therapy to minimize effects of prior, more intensive chemotherapy, and were used for the generation of DC, PHA-blasts and T-cell lines. Stimulation of PBMC was carried out with antigen-pulsed DC using four complete peptide libraries spanning the entire amino acid sequence of the TAAs WT1, Survivin, MAGE-A3 and PRAME.
Generation of DCs as well as T-cell lines was possible from all samples obtained, despite 76% of patients having low ALC counts of <1000/μl (Supplementary Table S1 ). At least a minimal expansion of 1.2-fold could be achieved in all patients with a maximum 31.4-fold expansion (mean 6.4-fold) after 3 stimulations (Fig. 1A) 
Ex vivo expanded TAA-specific T-cells recognize multiple target antigens with broad epitope specificity
Antigen specificity of the ex vivo expanded T-cell lines was evaluated weekly in response to the mix of TAA and individual antigens in IFNγ-ELISpot assay. Specific reactivity against the pooled TAAs after the initial stimulation could be seen in 54% of SR and 65% of HR patients (data not shown). After 3 stimulations, 92% of SR and 96% of HR patients showed specific responses against at least one antigen. There was almost equal distribution of SR versus HR patients showing reactivity against one (21% SR; 19% HR), two (21% SR; 23% HR), three (21% SR; 23% HR), or all four antigens (29% SR; 19% HR) ( Fig. 2A) . The majority of the expanded TAAspecific T-cell lines elicited responses against PRAME (79% SR vs. 69% HR), followed by WT1
(71% SR vs. 54% HR) and MAGE-A3 (58% SR vs. 57% HR). In contrast, T-cell responses to survivin were seen in a minority of patients (42% SR vs. 27% HR) (Fig. 2B) . Similarly, highest specificity as measured by spot counts in IFNγ-ELISpot assays, was seen in response to the (Fig. 2C) .
Cytolytic activity of T-cell lines was tested in a standard 51
Cr-release assay against peptidepulsed autologous PHA-blasts. Mean lysis of target cells pulsed with the pooled TAAs at an E:T ratio of 20:1 was 27% for CTL lines generated from the SR patients (range 0-77%) versus 31% for the HR patients (range 0-90%). Killing of targets pulsed with the individual antigens for the SR patients showed: mean 13% (range 0-66%) for WT1; mean 10%, (range 0-58%) for Survivin, mean 12%, (range 0-70%) for MAGE-A3 and mean 26%, (range 0-74%) for PRAME.
No appreciable differences in cytolytic responses were seen in T-cell lines generated from HR patients: mean 15%, (range 0-100%) for WT1, mean 8%, (range 0-58%) for Survivin, 16%, (range 0-68%) for MAGE-A3; and mean 21% (range 0-55%) for PRAME (Fig. 2D) . No killing (<6%) of unpulsed target cells was observed.
Polyclonal MHC class I and II-mediated T-cell responses can be elicited in vitro from patients on treatment for ALL
To compare the epitope-specific responses in T-cell lines generated from patients with ALL to those previously described in healthy donors (15, 24-28) we performed epitope mapping for WT1 in 11 T-cell lines. Reactivity against minipools of 15mer peptides overlapping by 11 amino acids spanning the whole sequence of WT1 were tested, as previously described (29).
Subsequently, confirmation of single peptide recognition and HLA-restriction was performed (15). The expanded T-cell line recognized both WT1 and PRAME (Fig. 3B) .
Epitope mapping was then performed for WT1 which showed reactivity against two regions within WT1, peptides #9/10 (QWAPVLDFAPPGASAYGSL) and peptides #71/72 (LCGAQYRIHTHGVFRGIQD). Using HLA class I and class II blocking antibodies, the overlapping sequence of peptides #71/72 was confirmed to contain an HLA-class I restricted epitope previously published by Woelfl et. al (28) (Fig. 3C , Table 1 ). In contrast, recognition of peptides #9/10 was HLA class II-restricted, as confirmed by blocking experiments. This 15mer peptide is known to contain both HLA class I and II restricted epitopes, however with different HLA-restrictions from that seen in our patient (24) (Fig. 3D, Table 1 ). In all, analysis of the WT1-specific T-cell responses in 11 patient-derived T-cell lines identified a total of eleven 15mer
class I and II-restricted peptides, as shown in Table 1 . The majority of these peptides have previously been described and identified to be immunogenic in healthy volunteers (15, (24) (25) (26) (27) (28) .
Hence, these results demonstrate that we can successfully generate antigen-specific T cell-lines from patients with ALL, and the spectrum of the specificity in these lines is similar to that of healthy donors with a range of class I and II restricted epitopes (15, 24) . Further, the polyfunctionality of the expanded tumor antigen-specific T cells is demonstrated in Fig. 3E where a T-cell line with specificity against all the targeted antigens released both IFNγ and TNFα in response to stimulation.
Antigen recognition and anti-leukemic activity against autologous bone marrow blast samples
We next investigated whether TAA-specific T-cells generated from patients with ALL were able to recognize and kill autologous leukemia cells in vitro. Co-culture experiments were set up for 8 patient-derived TAA-specific T-cell lines using, as targets, autologous ALL blasts obtained from bone marrow aspirates that had been cryopreserved at diagnosis. Antigen-specificity as well as short-and long-term co-cultures were evaluated in IFNγ-ELISpot, flow-based and CFU assays.
In addition, the co-culture supernatants were evaluated by IFNγ and IL4 ELISA assays.
Nonspecific T-cells derived from the same patient were used as controls. In ELISpot assay at a 1:1 ratio of leukemia cells to T-cells, the TAA-specific T-cells showed increased IFNγ-release residual blasts remaining compared to 46.8% in the controls (calculated relative to the initial leukemia cell counts on day 0)(p=0.04) (Fig. 4B) . Analysis of IFNγ and IL4-levels in the coculture supernatants showed high concentrations of IFNγ by TAA-specific T cells after 3 days of co-culture with autologous blasts (mean 630 ± 364 pg/10 6 cells/ml) compared to control T cells (mean 0pg/10 6 cells/ml)(p=0.04). Lower levels of IL4 were secreted by TAA-specific T cells (mean 19.6 ± 3.3 pg/10 6 cells/ml; control T cells mean 7.6 ± 1.1 pg/10 6 cells/ml) after co-culture with autologous blasts (p=0.017) (Fig. 4C) . Further, a specific inhibition of colony formation was observed in CFU assays after 14 days when leukemia blasts were co-cultured with TAA-specific T cells compared to control T cells. As shown in Fig. 4D , a mean relative inhibition of 42.3% of colony formation was observed (p=0.012).
on respectively. In patient ID#1032 (designated as SR), peptide reactivity against the pooled TAAs in ELISpot assay after initial (Fig. 5A) and three (Fig. 5B) stimulations showed recognition of WT1 and PRAME. Further, cytolytic activity against these antigens was demonstrated in a 51 Crrelease assay using peptide-pulsed autologous PHA-blasts as targets (Fig. 5C) . Co-culture of TAA-specific T-cells with autologous blasts showed reduction of autologous leukemia cells to 13% of the initial cell count after one day and to 4.8% after 3 days. In contrast, when nonspecific T cells derived from the same patient were incubated with autologous blasts, 23% of leukemia blasts remained on day 1 and 10% on day 3 of co-culture (Fig. 5D) . Reduction of leukemia cell numbers were also apparent when applying absolute quantification with FACS counting beads.
After 3 days, elimination of leukemia cells was observed when blasts were co-cultured with autologous TAA-specific T-cells but not control T cells (Fig. 5E) . Activation of TAA-specific T cells by the autologous blasts was further demonstrated in IFNγ-ELISpot assays, where the Tcells showed markedly increased IFNγ-production (mean 252 SFC/10 5 cells) compared to the control (mean 128 SFC/10 5 cells) (Fig. 5F) . To evaluate the expression of the targeted antigens on the ALL blasts, cytospins were stained by immunohistochemistry and showed weak positivity for MAGE-A3 and higher for Survivin (Fig. 5G) . Similarly, in supplementary Figures S2 to S8 the results of the co-culture experiments with autologous blasts of the remaining patients are shown, including the 3-day co-culture and ELISpot assays as well as the immunohistochemistry of the leukemia blasts. There was no correlation between the generation of effective CTL and leukemia antigen expression in the blasts in the 8 patients where leukemia blasts and peripheral blood samples were available.
DISCUSSION
Patients with ALL who have high risk disease or who relapse have a high rate of mortality and the best chance of cure is the allogeneic HSCT. There is a need for more effective treatment options for patients not eligible for allogeneic transplant and immunotherapy may be most effective for preventing relapse in high risk patients after chemotherapy. Therefore, we sought to develop a strategy to generate autologous T cells that target multiple TAAs and demonstrate specific anti-leukemic activity for use as adoptive T-cell immunotherapy to prevent relapse in pediatric ALL. Our rationale for obtaining samples during maintenance therapy was to demonstrate feasibility of collection at this time point for potential use as a front-line strategy, to augment therapy in high-risk patients in first remission. We show here that TAA-specific T cells can be generated from patients with ALL during maintenance therapy regardless of NCI risk group and in spite of low lymphocyte counts at the time of sample acquisition. Patients with high risk ALL might have more compromised immune systems, correlating with their poor outcome.
Nevertheless, we observed no difference in the quality of TAA-specific T cells that could be generated from high and standard risk patients. None of the commonly known risk factors for relapse, including age and gender, affected our ability to ex vivo expand TAA-specific T cells from these patients and extensive in vitro testing showed anti-leukemic activity of the expanded products against autologous ALL blasts in long-and short-term co-culture experiments.
Antigen-specific responses were detectable within 7-10 days after just a single stimulation in more than half of the tested patients, indicating that the immunosuppression due to the chemotherapeutic drugs administered during maintenance therapy did not preclude the expansion of TAA-specific T cells in vitro. Moreover, upon subsequent re-stimulation, TAAspecific T cells were expanded from over 90% of patients, suggesting that the in vivo immune suppressive environment could be overcome in vitro. At least a minimal 1.2-fold expansion of the autologous T-cell lines was possible in all cases, using methods approved for good manufacturing practices. Nevertheless, for a clinical scale product the conditions need to be adjusted to achieve cell numbers necessary for infusion, e.g. through use of gas-permeable cell culture flasks (30). While it is encouraging that our TAA-specific T cells reduced autologous leukemia blasts in coculture experiments, it remains to be determined whether TAA-specific T cells have therapeutic efficacy in patients with ALL. It would be possible to generate a SCID/hu mouse model of ALL to further test the anti-leukemic effect of TAA-specific T cells. However, while such a model, using autologous T cells to prevent or treat ALL, might yield positive results, it would not guarantee success in man. Conversely, were the TAA-specific T cells ineffective in the murine model, we
would not wish to abandon evaluating TAA-specific T cells in a carefully designed clinical trial, where we can track the fate and function of in vitro generated TAA and evaluate anti-leukemic efficacy by measuring residual disease. Given the safety of infused TAA-specific T cells generated in healthy donors,(13) and the lack of relevance of animal models for establishing
Author Manuscript Published OnlineFirst on July 9, 2013; DOI: 10.1158/1078-0432.CCR-13-0955 safety, our next step will be to generate GMP grade TAA-specific T cells for a phase 1 clinical trial.
This study shows that the generation of TAA-specific T-cell lines from the peripheral blood of patients with ALL on maintenance therapy irrespective of NCI risk group is feasible, and that these T cells show anti-leukemic activity against autologous blasts in vitro. Therefore, adoptive immunotherapy with autologous TAA-specific T cells to boost anti-leukemic immune responses and prevent relapse appears to be a promising approach and may improve outcomes in high risk ALL both in the front-line setting, and as a new approach to treat relapsed patients not eligible for allogeneic stem cell transplant in combination with other therapeutic options.
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